Sofinnova Partners, NVIDIA Team Up for Life Science Innovation

Sofinnova Partners is collaborating with NVIDIA to support its portfolio of life sciences startups. The collaboration delivers significant Graphics Processing Unit (GPU) credits to select Sofinnova portfolio companies, effectively giving access to the same computational firepower used by Silicon Valley tech titans.

Amidst increasing demand for compute resources driven by AI, Sofinnova’s portfolio companies will be able to access NVIDIA Blackwell and other NVIDIA architecture GPUs through  NVIDIA DGX Cloud Lepton, an artificial intellligence (AI) platform and marketplace connecting developers to global AI infrastructure.

BioCorteX, Bioptimus, Cure51 and Latent Labs—four of Europe’s most promising digital medicine startups—will gain access to computing resources through DGX Cloud Lepton, enabling them to process biological data sets and run computational models that would have taken months, completing them in days. 

Cure51, a pioneer in decoding the biology of exceptional cancer survivors, tested NVIDIA Parabricks, a GPU-accelerated genomics toolkit, and achieved up to 17x faster processing with NVIDIA H100 GPUs and more than twice the cost savings with NVIDIA L4 GPUs compared to their CPU baseline—dramatically accelerating their ability to analyze complex genomic data and scale their survivor-based insights.

“This collaboration supercharges computation for life sciences innovation,” said Antoine Papiernik, chairman and managing partner at Sofinnova Partners. “The convergence of biology, AI, computation, and data isn’t just our investment thesis—it’s the defining battleground of the next decade. From our digital medicine strategy to our own proprietary AI platform Sofinnova.ai, we recognize the transformative potential of AI across our entire domain. By securing access to NVIDIA’s infrastructure, we’re not just funding companies; we’re empowering them with the computational backbone needed to outperform incumbents and redefine what’s possible in drug discovery, precision medicine, and scalable solutions that address both human health and sustainability.” 

Sofinnova Partners is a European venture capital firm in life sciences, specializing in healthcare and sustainability. Based in Paris, London, and Milan, the firm brings together professionals worldwide with strong scientific, medical, and business expertise. Sofinnova Partners is a hands-on company builder across the entire value chain of life sciences investments, from seed to later-stage. Founded in 1972, Sofinnova Partners is a deeply established venture capital firm in Europe, with 50 years of experience backing more than 500 companies. Sofinnova Partners currently manages more than €4 billion in assets.